Please login to the form below

Not currently logged in
Email:
Password:

Listeria-based vaccine could halt breast cancer

Researchers in conjunction with US-based biotechnology company Advaxis develop Listeria-derived vaccines which could halt or even reverse breast cancer

Researchers from the University of Pennsylvania in conjunction with US-based biotechnology company, Advaxis, have developed of a series of cancer-fighting vaccines which may halt or even reverse breast cancer.

The vaccine was developed from investigations into the Listeria monocytogenes bacterium which grows in milk, cheese and other dairy products. The micro-organism creates a strong immune response to the presence of cancer cells.

Yvonne Paterson, professor of microbiology at the University of Pennsylvania and scientific director at Advaxis, presented evidence of the cancer-fighting properties of live, modified Listeria-based vaccines, which eradicated several types of rapidly growing cancers in mice studies.

Listeria blocks the immune system's response when it gains access to the body, helping it to spread. Researchers observed a mechanism whereby the organism directed the immune response to attack cancer cells. As a result, the vaccines taught the immune system to mount a specialised, targeted response lethal to cancer cells.

Advaxis is now preparing for clinical trials of Lovaxin B, which is aimed at treating women with pre-existing breast cancer.

Professor John Rothman, vice-president of clinical development at Advaxis, said: "While it may be a few years before we complete the studies, the promise of a cancer vaccine is truly a milestone that we hope may be attainable."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics